Yvonne McGrath - Mar 11, 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Scientific Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Mar 11, 2022
Transactions value $
$0
Form type
4
Date filed
3/14/2022, 08:02 PM
Previous filing
Mar 2, 2022
Next filing
Mar 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +85K $0.00 85K Mar 11, 2022 Common Stock 85K $36.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest over 4 years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the Reporting Person's continued service to the Issuer.